Neurocrine Biosciences Presents New Phase 4 Analysis Showing INGREZZA Improves Function & Quality Of Life In Tardive Dyskinesia Patients

+0.87%

Neurocrine Biosciences, Inc.

NBIX

0.00

Patients Treated with INGREZZA® (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life Measures
Findings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research Conference

SAN DIEGO, May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the presentation of new analyses from a Phase 4 randomized withdrawal study (NCT03891862) showing patients with tardive dyskinesia who received continued treatment with INGREZZA® (valbenazine) capsules reported improvements across functional and health-related quality of life measures. These findings complement recently announced patient-reported outcome data from the Phase 4 KINECT-PRO™ study of INGREZZA, which was the first of its kind to specifically measure and report clinically meaningful improvements in the impact of tardive dyskinesia. The analyses were presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference in Montreal, Canada.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Neurocrine Biosciences (NBIX): Assessing Valuation After Strong Q3 Results and Pipeline Progress

Outlook Therapeutics Re-Submits Biologics License Application To FDA For ONS-5010 For Wet AMD

Corvus Pharmaceuticals To Present Final Phase 1 Data On Soquelitinib For R/R T Cell Lymphoma At ASH 2025

Kura Oncology Gets $30M Milestone Payment Under Partnership Agreement With Kyowa Kirin In Dosing First Participant In Second KOMET-017 Phase 3 Registration Trials Of Ziftomenib

Sarepta Therapeutics Says ESSENCE Study Did Not Achieve Statistical Significance On Its Primary Endpoint; Says 'the study was impacted by the COVID-19 pandemic and, when COVID-impacted data is excluded, meaningful treatment effect is seen on the p...

PRESS DIGEST-Financial Times - November 4

How Investors May Respond To ANI Pharmaceuticals (ANIP) Analysts’ Bullish Earnings and Revenue Forecasts

Reported Earlier, Ascentage Pharma To Present Olverembatinib Global Phase III POLARIS-1 Dataset And Lisaftoclax Phase II Oral Study At ASH 2025